Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: Nature. 2019 Dec 25;578(7795):444–448. doi: 10.1038/s41586-019-1911-y

Extended Data Figure 1. Expanded CAMERA data set.

Extended Data Figure 1

a, Linear association between change in body weight and change in plasma GDF15 between 0 and 18 months among metformin treated participants (n=74, Spearman correlation r=-0.26, two-sided p=0.024). Red line is linear regression slope, and grey area is 95% confidence interval for slope.

b, Absolute and relative differences in plasma GDF15 concentration between metformin and placebo groups at each time point (total 625 observations in 173 participants).

c,d, Individual measures of plasma GDF15 levels in placebo group (c) and metformin group (d) over time.

e, Plasma GDF15 concentration (95%CI) in overweight or obese non-diabetic participants with known cardiovascular disease randomised to metformin or placebo in CAMERA; modelled using a mixed linear model as per Figure 1 and grouped as “all participants” and “ all participants not reporting diarrhoea and vomiting”. Model includes all participants